Journal of Rheumatic Diseases

Table. 1.

Characteristics of AAV patients with at diagnosis and during follow-up (n=203)

Variables Values
At the time of diagnosis
Demographic data
Age (yr) 59.0 (18.5)*
Male sex 72 (35.5)
AAV subtypes
MPA 112 (55.2)
GPA 54 (26.6)
EGPA 37 (18.2)
ANCA positivity
MPO-ANCA (or P-ANCA) positivity 136 (67.0)
PR3-ANCA (or C-ANCA) positivity 34 (16.7)
Both ANCA positivity 8 (3.9)
ANCA negativity 41 (20.2)
AAV-specific indices
BVAS 12.0 (10.5)*
FFS 1.0 (1.0)*
Clinical manifestations at diagnosis
Generalized symptoms 88 (43.3)
Skin 44 (21.7)
Mucous membrane and eyes 11 (5.4)
Ear nose throat 92 (45.3)
Lungs 120 (59.1)
Heart 43 (21.2)
Gastrointestine 9 (4.4)
Kidneys 127 (62.6)
Central or peripheral nervous systems 61 (30.0)
Comorbidities at diagnosis
Diabetes mellitus 52 (25.6)
Hypertension 78 (38.4)
Chronic kidney disease (stages 3~5) 58 (28.6)
Hyperlipidaemia 35 (17.2)
Interstitial lung disease 56 (27.6)
Acute-phase reactants
ESR (mm/hr) 54.0 (68.0)*
CRP (mg/L) 11.7 (60.5)*
BMI (kg/m2) 22.8 (3.6)*
Serum albumin (g/dL) 3.7 (1.1)*
mBMI (kg · g/m2 · L) 813.2 (270.7)*
During the follow-up period
Mortality during follow-up
All-cause mortality 25 (12.3)
Follow-up duration based on all-cause mortality (mo) 36.6 (66.1)*
Medications administered during follow-up
Glucocorticoids 189 (93.1)
Cyclophosphamide 101 (49.8)
Rituximab 33 (16.3)
Azathioprine 113 (55.7)
Mycophenolate mofetil 24 (11.8)
Tacrolimus 10 (4.9)
Methotrexate 21 (10.3)

Values are expressed as a median (interquartile range)* or number (%). AAV: ANCA-associated vasculitis, ANCA: antineutrophil cytoplasmic antibody, BMI: body mass index, MPA: microscopic polyangiitis, GPA: granulomatosis with polyangiitis, EGPA: eosinophilic GPA, MPO: myeloperoxidase, P: perinuclear, PR3: proteinase 3, C: cytoplasmic, BVAS: Birmingham vasculitis activity score, FFS: five-factor score, CRP: C-reactive protein, mBMI: modified body mass index.

J Rheum Dis 2022;29:154~161 https://doi.org/10.4078/jrd.2022.29.3.154
© J Rheum Dis